Health Condition 1: L408- Other psoriasis
Conditions
Interventions
Intervention1: methotrexate and apremilast: Apremilast will be given orally in the dose of 30mg twice daily for 4 months. Initial dose titration will be done for the �rst 7 days. The �rst dose, 1
Sponsors
nil
Eligibility
Inclusion criteria
Inclusion criteria: Histopathologically and dermoscopically proven Palmoplantar psoriasis with mPPASI > 10, DLQI > 3
Exclusion criteria
Exclusion criteria: 1.Deranged CBC, LFT, urea, creatinine 2.Pregnancy, lactation 3.Alcoholics 4.Palmoplantar pustulosis 5.Concomitant plaque psoriasis involving sites other than knuckles and nails; erythrodermic and pustular psoriasis, and psoriatic arthritis requiring concomitant systemic anti-psoriatic treatments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| i)To assess the response to treatment with systemic methotrexate vs methotrexate and apremilast in patients with Palmolplantar psoriasis ii) To investigate the correlation between clinical severity of Palmoplantar Psoriasis and patientsâ?? quality of life by using DLQI Timepoint: Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| ii) To investigate the correlation between clinical severity of Palmoplantar Psoriasis and patientsâ?? quality of life by using DLQI Timepoint: 4 months | — |
Countries
India
Contacts
Public ContactTrashita Hassanandani
IMS and SUM Hospital
Outcome results
None listed